# A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis

Source: https://onco.cc/trials/nct06149559/  
OnCo record `nct06149559` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial of rozanolixizumab in childhood cancers, run by UCB Biopharma SRL, active and no longer recruiting.

## Summary

A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis is a phase 2/3 interventional study registered as NCT06149559 by UCB Biopharma SRL, with 14 participants enrolled, started 2024-06-14 and due to reach its primary completion in 2026-10-05. Interventions recorded: rozanolixizumab.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06149559
- Phase: 2/3
- Setting: An Open-label, Single-arm Study Evaluating the Activity, Safety, and Pharmacokinetics of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis
- Sponsor: UCB Biopharma SRL
- Enrolled: 14

## Sources

- ClinicalTrials.gov NCT06149559: https://clinicaltrials.gov/study/NCT06149559

## Connected records

- cancers: [Childhood cancers (all types)](https://onco.cc/cancers/childhood-cancers/)
- companies: [UCB](https://onco.cc/companies/ucb/)

---
JSON: https://onco.cc/api/v1/entities/nct06149559.json